BLINN MARK A 4
4 · TEXAS INSTRUMENTS INC · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
Texas Instruments (TXN) Director Mark A. Blinn Exercises Options, Sells Shares
What Happened
Mark A. Blinn, a director of Texas Instruments (TXN), exercised multiple stock option tranches on Feb 5, 2026 to acquire a total of 2,572 shares for aggregate exercise costs of about $451,344 (breakdown: 628 @ $174.81 = $109,781; 540 @ $174.10 = $94,014; 767 @ $167.42 = $128,411; 637 @ $187.03 = $119,138). On the same day he sold 3,144 shares in an open-market transaction for a weighted average price of $221.58, resulting in proceeds of about $696,647. The filing shows corresponding derivative-to-stock conversions recorded at $0 (typical reporting for exercised options converting to shares).
Key Details
- Transaction date: Feb 5, 2026 (Form 4 filed Feb 6, 2026). Filing appears timely.
- Sales: 3,144 shares sold at a weighted average price of $221.58 (range reported $221.00–$221.93). Issuer will provide a detailed price-by-price breakout on request (Footnote F1).
- Option exercises: 2,572 shares exercised across four option tranches with exercise prices of $174.81, $174.10, $167.42 and $187.03 (Footnotes F5–F8 describe vesting schedule for the options).
- Shares owned after transaction: not disclosed in the provided excerpt of the filing.
- Trust/ownership notes: several footnotes indicate some shares are held in trusts for family members or held in trust for the reporting person with disclaimers of beneficial ownership or trustee status (F2–F4).
- No 10b5-1 plan, tax-withholding, or late-filing flag is indicated in the provided details.
Context
This is a common insider pattern: exercising vested options and selling shares the same day. The zero-dollar derivative dispositions reflect conversion of options into shares. Because the sale quantity (3,144) exceeds the exercised shares (2,572), Blinn likely sold a mix of newly exercised shares and previously held shares or trust-held shares; the filing’s footnotes clarify some shares are held in trusts. These transactions are factual disclosures and do not, by themselves, indicate Blinn’s longer-term view on TXN.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-02-05$174.81/sh+628$109,781→ 12,870 total - Exercise/Conversion
Common Stock
2026-02-05$174.10/sh+540$94,014→ 13,410 total - Exercise/Conversion
Common Stock
2026-02-05$167.42/sh+767$128,411→ 14,177 total - Exercise/Conversion
Common Stock
2026-02-05$187.03/sh+637$119,138→ 14,814 total - Sale
Common Stock
[F1]2026-02-05$221.58/sh−3,144$696,647→ 11,670 total - Exercise/Conversion
NQ Stock Option (Right to Buy)
[F5]2026-02-05−628→ 0 totalExercise: $174.81Exp: 2032-01-27→ Common Stock (628 underlying) - Exercise/Conversion
NQ Stock Option (Right to Buy)
[F6]2026-02-05−540→ 540 totalExercise: $174.10Exp: 2033-01-26→ Common Stock (540 underlying) - Exercise/Conversion
NQ Stock Option (Right to Buy)
[F7]2026-02-05−767→ 1,533 totalExercise: $167.42Exp: 2034-01-25→ Common Stock (767 underlying) - Exercise/Conversion
NQ Stock Option (Right to Buy)
[F8]2026-02-05−637→ 1,914 totalExercise: $187.03Exp: 2035-01-27→ Common Stock (637 underlying)
- 3,046(indirect: By Trust)
Common Stock
[F2] - 6,000(indirect: By Trust)
Common Stock
[F3] - 6,000(indirect: By Trust)
Common Stock
[F4]
Footnotes (8)
- [F1]The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $221.00 to $221.93. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price.
- [F2]Shares held in Trust for the benefit of family member; reporting person shares investment control. Beneficial ownership by reporting person disclaimed.
- [F3]Shares held in Trust for the benefit of family member of which reporting person is trustee. Beneficial ownership by reporting person disclaimed.
- [F4]Shares held in Trust for the benefit of the reporting person. Reporting person is the sole trustee.
- [F5]The option became exercisable in four equal annual installments beginning on January 27, 2023.
- [F6]The option became exercisable in four equal annual installments beginning on January 26, 2024.
- [F7]The option became exercisable in four equal annual installments beginning on January 25, 2025.
- [F8]The option became exercisable in four equal annual installments beginning on January 27, 2026.